Provided herein are non-invasive in vivo imaging methods to evaluate efficacy of a therapeutic intervention for neuromuscular diseases by determining the level and/or localization of a detectable marker that is influenced by another protein which is a target of the therapeutic intervention. Non-invasive imaging methods disclosed herein can involve in vivo molecular imaging such as PET or SPECT, and/or morphological imaging such as MRI or CT.
